share_log

Corcept Therapeutics Submits New Drug Application To FDA For Its Proprietary, Selective Cortisol Modulator, Relacorilant, To Treat Patients With Cushing's Syndrome

Benzinga ·  Dec 30, 2024 17:16
Corcept Therapeutics Submits New Drug Application To FDA For Its Proprietary, Selective Cortisol Modulator, Relacorilant, To Treat Patients With Cushing's Syndrome
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment